BackEdwards Lifesciences Overview

Edwards Lifesciences Receivables

Track Edwards Lifesciences's receivables ($960M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$955.70M
↑ 5.88% YoYΔ $53.10M vs prior year quarter

Peer trimmed avg / median

Loading

Edwards Lifesciences Receivables History

Loading

Edwards Lifesciences vs. peers: Receivables Comparison

Loading

Edwards Lifesciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Edwards Lifesciences (EW) FAQ

As of the most recent data (June 2026), EW shows a receivables of $960M. That compares with $900M in the prior-year period — up 5.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EW's receivables is now $960M (was $900M) — a 5.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Edwards Lifesciences is outperforming or lagging.

Tracking EW's receivables over time shows whether Edwards Lifesciences is scaling, shrinking, or reshaping that part of the business. The current reading is $960M That compares with $900M in the prior-year period — up 5.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Edwards Lifesciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $960M) with ownership activity and broader fundamentals.

Edwards Lifesciences's receivables is $960M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.